Literature DB >> 9357016

Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specific for A beta 40 and the A beta that ends at residues alanine42/threonine43 (A beta 42).

H Akiyama1, H Mori, N Sahara, H Kondo, K Ikeda, T Nishimura, T Oda, P L McGeer.   

Abstract

Amyloid beta-protein (A beta) deposits in the cerebral cortices of patients with Alzheimer's disease (AD) were investigated immunohistochemically to determine their carboxy terminal sequences. Antibodies specific for A beta terminating at residue valine40 (A beta 40) and at residues alanine42/threonine43 (A beta 42) were used. Virtually all parenchymal A beta deposits were positive for A beta 42. Many of these deposits were also partially or completely labeled for A beta 40. The degree of A beta 40 labeling varied from area to area within a given brain and from AD case to AD case. In contrast to parenchymal deposits, A beta 40 labeled essentially all the vascular deposits which constitute amyloid angiopathy (AA), with A beta 42 occurring variably in some of these deposits. Occasional AA was found, however, in which A beta 42 predominated or was exclusively deposited. Such a diversity of A beta species, both in brain parenchyma and in AA, suggests that multiple C-terminal processing mechanisms occur in the cell types responsible for these deposits.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9357016     DOI: 10.1023/a:1021910729963

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  23 in total

1.  Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia.

Authors:  H Yamaguchi; Y Nakazato; M Shoji; K Okamoto; Y Ihara; M Morimatsu; S Hirai
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

2.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

3.  Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam.

Authors:  C Schwab; J C Steele; H Akiyama; P L McGeer
Journal:  Acta Neuropathol       Date:  1996-10       Impact factor: 17.088

4.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.

Authors:  J E Maggio; E R Stimson; J R Ghilardi; C J Allen; C E Dahl; D C Whitcomb; S R Vigna; H V Vinters; M E Labenski; P W Mantyh
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

5.  Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study.

Authors:  A Tamaoka; N Sawamura; A Odaka; N Suzuki; H Mizusawa; S Shoji; H Mori
Journal:  Brain Res       Date:  1995-05-08       Impact factor: 3.252

6.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

7.  Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome.

Authors:  T Iwatsubo; D M Mann; A Odaka; N Suzuki; Y Ihara
Journal:  Ann Neurol       Date:  1995-03       Impact factor: 10.422

8.  A beta40 is a major form of beta-amyloid in nonhuman primates.

Authors:  M Gearing; J Tigges; H Mori; S S Mirra
Journal:  Neurobiol Aging       Date:  1996 Nov-Dec       Impact factor: 4.673

9.  Brain microglia constitutively express beta-2 integrins.

Authors:  H Akiyama; P L McGeer
Journal:  J Neuroimmunol       Date:  1990-11       Impact factor: 3.478

10.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

View more
  5 in total

1.  A History of Senile Plaques: From Alzheimer to Amyloid Imaging.

Authors:  Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2022-05-20       Impact factor: 3.148

2.  Insights into Cerebral Amyloid Angiopathy Type 1 and Type 2 from Comparisons of the Fibrillar Assembly and Stability of the Aβ40-Iowa and Aβ40-Dutch Peptides.

Authors:  Jitika Rajpoot; Elliot J Crooks; Brandon A Irizarry; Ashley Amundson; William E Van Nostrand; Steven O Smith
Journal:  Biochemistry       Date:  2022-06-06       Impact factor: 3.321

3.  Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate Aβ in Down Syndrome and Sporadic Alzheimer's Disease.

Authors:  Violetta N Pivtoraiko; Tamara Racic; Eric E Abrahamson; Victor L Villemagne; Benjamin L Handen; Ira T Lott; Elizabeth Head; Milos D Ikonomovic
Journal:  Front Aging Neurosci       Date:  2021-08-13       Impact factor: 5.702

4.  Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease.

Authors:  Grace M Lloyd; Jorge A Trejo-Lopez; Yuxing Xia; Karen N McFarland; Sarah J Lincoln; Nilüfer Ertekin-Taner; Benoit I Giasson; Anthony T Yachnis; Stefan Prokop
Journal:  Acta Neuropathol Commun       Date:  2020-03-12       Impact factor: 7.801

5.  The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes.

Authors:  Timo Jan Oberstein; Janine Utz; Philipp Spitzer; Hans Wolfgang Klafki; Jens Wiltfang; Piotr Lewczuk; Johannes Kornhuber; Juan Manuel Maler
Journal:  Front Mol Neurosci       Date:  2021-01-12       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.